Kimberly Eyer

Endometriosis involves ectopic endometrial tissue causing pain and infertility. Validated and Promising Interventions include Hyperbaric Oxygen Therapy (HBOT), Low Nickel Diet, and Metronidazole therapy.

Overview Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-beta (Aβ) plaques, neurofibrillary tangles, neuroinflammation, and metabolic dysfunction, ultimately leading to cognitive decline and dementia. Emerging research highlights the microbiota-gut-brain axis as a crucial factor in AD pathogenesis, with gut dysbiosis contributing to neuroinflammation, immune dysregulation, and blood-brain barrier permeability. Microbial metabolites, such […]

Hashimoto’s Thyroiditis (HT) is an autoimmune disease that progressively damages the thyroid, often causing hypothyroidism and affecting women disproportionately. Research links HT to gut dysbiosis via the gut–thyroid axis and highlights heavy metals like nickel, arsenic, and lead as contributors to oxidative stress and thyroid dysfunction.

Irritable Bowel Syndrome (IBS) is a common gastrointestinal disorder characterized by symptoms such as abdominal pain, bloating, and altered bowel habits. Recent research has focused on the gut microbiota’s role in IBS, aiming to identify specific microbial signatures associated with the condition.

Parkinson’s disease is increasingly recognized as a systemic disorder involving coordinated disturbances across the gut–brain axis, rather than a condition confined to dopaminergic neurodegeneration alone. Converging evidence implicates gut dysbiosis, altered microbial metabolites, impaired intestinal barrier integrity, and metal dyshomeostasis as upstream drivers of neuroinflammation and alpha-synuclein pathology. These interconnected microbiome, metabolomic, and metallomic signals provide a mechanistic framework for understanding disease initiation, progression, and therapeutic targeting beyond the central nervous system.

This paper proposes that Parkinson’s disease vulnerability is partly a pigment and metal-handling problem. MC1R loss-of-function biases neuromelanin toward pheomelanin-like subunits, weakening iron sequestration and amplifying oxidative stress. We argue that MC1R agonists, including melanotan peptides, could restore eumelanin-like buffering, reduce ferroptosis, and dampen neuroinflammation.

This hypothesis reframes the red hair MC1R–Parkinson’s link as a metal-handling phenotype. Pheomelanin-biased neuromelanin may lose eumelanin casing capacity, saturate with iron earlier, release labile iron, and amplify ROS and ferroptosis in dopaminergic neurons, yielding a modifiable risk target.

This study reveals that inflammatory cytokines (IL-6, IL-10, IL-13, and TNF-α) are significantly elevated in the peritoneal fluid of endometriosis patients with infertility. These findings suggest their potential role as diagnostic biomarkers and therapeutic targets for managing reproductive complications in endometriosis.

This study identifies intrauterine microbial colonization in endometriosis, with enriched Streptococcaceae, Staphylococcaceae, and Enterobacteriaceae. GnRHa therapy exacerbated microbial imbalances, highlighting potential therapeutic targets for managing inflammation and infection in endometriosis. Findings suggest microbial modulation may enhance treatment outcomes.

This study maps the microbiota composition along the reproductive tract in endometriosis patients, revealing microbial dysbiosis, reduced Lactobacillus, and increased Pseudomonas and Sphingobium in upper reproductive sites. These findings suggest potential microbial contributions to inflammation, lesion persistence, and new biomarkers for diagnosing endometriosis.

Graves’ disease patients display a distinct gut microbiota signature, characterized by reduced diversity and altered abundance of key microbial taxa, including increased Bacilli, Prevotella, and Megamonas, and decreased Ruminococcus and Alistipes, suggesting a role for the microbiome in GD pathogenesis.

Graves’ disease patients show distinctive gut microbiota profiles, with increased Bacteroidetes and specific pro-inflammatory bacteria, despite no difference in overall diversity. Key taxa correlate with clinical GD parameters, highlighting their potential as diagnostic biomarkers and supporting a role for gut dysbiosis in GD pathogenesis.

This cross-sectional study found that Graves’ disease patients have distinctly altered gut microbiota—lower Firmicutes, higher Bacteroidetes, and reduced butyrate-producers—suggesting a role for the microbiome in disease pathogenesis and as a diagnostic biomarker.

This study demonstrates that Graves’ disease and Hashimoto’s thyroiditis patients share distinct gut microbiome signatures—particularly involving Bacillus, Blautia, and Ornithinimicrobium—and a common enrichment of the ABC transporter pathway, supporting a microbiome-driven mechanism in autoimmune thyroid disease pathogenesis.

This study identified distinct alterations in gut microbiota composition and function in Graves’ disease and Graves’ orbitopathy patients compared to healthy controls, highlighting specific microbial taxa and metabolic pathways that may contribute to disease mechanisms and serve as future biomarkers.

Integrated microbiome-metabolome study reveals dysbiosis and metabolic shifts in Graves’ disease and hypothyroidism, highlighting potential biomarkers like depleted Bacteroides for thyroid disorders.

This study reveals distinct compositional changes in the gut microbiota of Graves’ disease patients, notably increased Bacteroidetes and Prevotellaceae and decreased Firmicutes and Lachnospiraceae, suggesting potential microbial biomarkers and a role for gut dysbiosis in the disease’s pathogenesis.

This study reveals that Graves’ disease patients exhibit distinct gut microbiota signatures, with increased Bacteroidetes and Prevotellaceae and decreased Firmicutes and Lachnospiraceae, strongly associated with thyroid function markers. These microbial shifts may play a role in GD pathogenesis and serve as potential clinical biomarkers.

This study identified distinctive alterations in gut microbiota in Graves’ disease, including reduced diversity and specific taxonomic shifts. Key microbial signatures correlated with thyroid autoimmunity, highlighting potential diagnostic biomarkers and suggesting that microbiome modulation may offer new therapeutic avenues for Graves’ disease.

This study demonstrates that gut microbiome composition and function differ significantly between Graves’ disease and Graves’ orbitopathy, with specific taxa correlating with thyroid autoimmunity. These findings highlight the potential of gut microbial markers for distinguishing GO from GD and understanding disease mechanisms.

Erectile dysfunction (ED) involves the consistent inability to sustain an erection, frequently connected to broader health issues and disturbances in the gut microbiome.

This study found that gut microbiota in Hashimoto’s thyroiditis patients differs markedly from healthy controls, with enriched Escherichia coli and depleted Prevotella. These microbial shifts support the hypothesis that dysbiosis contributes to autoimmune thyroid inflammation and may offer targets for intervention.

Oral microbiota in new-onset rheumatoid arthritis shows unique enrichment of Prevotella, Leptotrichia, and Anaeroglobus, independent of periodontitis severity. These taxa may act as microbial triggers or biomarkers for autoimmunity, suggesting the oral microbiome’s relevance in RA onset and potential for diagnostic or therapeutic targeting.

This study shows that the oral microbiota in early rheumatoid arthritis includes enriched Tannerella forsythia and Streptococcus anginosus, correlating with increased periodontal attachment loss. These findings suggest early microbial dysbiosis may influence RA pathogenesis and serve as diagnostic biomarkers or targets for preventive care.